[Circulatory action and adverse effects of 3-carbethoxyamino-5-dimethylamino-acetyl-iminodibenzyl hydrochloride (Bonnecor, AWD 19-166, GS 015) in the dog and cat].
The haemodynamic and cardiac effects of GS 015, a substance of the series of the novel 5-(dialkyl-aminoacyl)-3-carbalkoxyamino-10,11-dihydro-5H-dibenz-[b ,f]-azepines with very potent antifibrillatory and antiarrhythmic actions, are studied on anaesthetized dogs and cats by means of the catheter technique. The clinical symptoms and the therapeutic range were tested on conscious animals. On the strength of the present results it can be stated that GS 015, given at pharmacodynamically effective doses, does not cause any circulatory side effects. A negative inotropic effect appears only at increased doses. Like other antiarrhythmic drugs, GS 015 possesses a limited therapeutic range which should be taken into consideration particularly in case of cardiac insufficiency. But an application seems possible also in patients during the acute stage of myocardial infarction.
D000758:Anesthesia; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D002415:Cats; D003326:Coronary Circulation / Q000187:drug effects; D003984:Dibenzazepines / Q000494:pharmacology*; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects*; D007275:Injections, Intravenous; D009200:Myocardial Contraction / Q000187:drug effects; D013045:Species Specificity
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; C048166:tiracizine
Kreislaufwirkungen und Nebenwirkungen von 3-Carbethoxyamino-5-dimethylamino-acetyl-iminodibenzyl-hydrochlorid (Bonnecor, AWD 19-166, GS 015) an Hund und Katze.